The global Non-Insulin Therapies market size is estimated at 33,941 million USD with a CAGR of 10.2% during the forecasted period from 2021-2028.
Non-insulin treatments are largely used in type 2 diabetes patients, where body either doesn't transport enough insulin or can't effectively use the insulin it creates. On-insulin-based drug mechanism incorporates several systems of action to decrease blood glucose level and retain it for ultimate glycemic control.
The key factor driving the growth of Non-Insulin Therapies market is attributed to rise in number of diabetes patients. In addition, growing demand for combination therapy along with rapid improvement in diabetic treatment is expected to boost this market. Moreover, factors such as rise in research & development activities is creating opportunities for the growth of this market.
On the other hand, patent expiries of presently available drugs can limit the growth of Non-Insulin Therapies market. Also, high price of novel frugs is likely to limit the market growth.
Product Market Overview
Sulfonylureas, alpha-glucosidase, glinides etc. are the first class of non-insulin drugs in the market. However, lately, new world drugs classes such as GLP-1 agonists and DPP4 inhibitors have become a mainstream candidate in diabetes type 2 treatment. As a result, the GLP-1 agonists market is estimated to grow with a robust CAGR over the forecast period.
Oral non-insulin therapies for diabetes type 2 hold lions shares in the market, accounting for nearly 90% of the market share. Easy consumption and availability of oral drugs attribute to rapid market growth. However, over the forecast period, injectable non-insulin therapy will witness the fastest growth rate of over 7% CAGR from 2019-2025.
Regional Market Overview
U.S non-insulin therapies market accounted for the largest market share worldwide. Technological advancement and adoption, high spending on diabetes care by patients and healthcare, increasing incidence of diabetes type 2 are some of the major factors driving the U.S market growth. According to international diabetes federation, in the U.S, more than 17 thousand new cases of diabetes emerge every year.
The Asia Pacific non-insulin therapies market is poised to expand with a robust CAGR of over 7% during the forecast timeframe. Diabetes prevalence is rapidly increasing in Asian countries. Diabetes, which was considered as the disease of abundance exclusively seen in industrialized nations, is alarmingly becoming a major hurdle for healthcare systems in developing countries of Asia such as India and China. Moreover, smaller economies, such as Taiwan and other south Asia countries, will experience significant growth in the diabetes care market. Taiwan is one of the fastest-growing market place.
China non-insulin therapies market is poised to expand at an exceptional rate due to increasing incidence of diabetes type 2, healthcare sectors expansion, and development of new facilities and rising awareness and spending related to diabetes care cities. A large unmet need for diabetes type 2 care is waiting to be addressed by the advanced introduction of advanced drugs in the industry. As a result, the market is expected to witness growth, especially in tier 1 cities of the country. In the near future, as per estimates, Chinaâs market is most likely to outpace European market.
Key Industry Participants
Eurofarma Laboratory, Merck Sharp & Dohme Group, Eli Lilly, Pfizer, AstraZeneca, Novo Nordisk, Sanofi are the major industry participants in global non-insulin therapies market. New technology-based products, geographic expansion, mergers and acquisitions are some of the major strategies implemented by companies to gain market share.
- Insulin Secretagogues
- Alpha-glucosidase inhibitors
- Dipeptidyl peptidase-4 (DPP-4) inhibitors
- Sodium-Glucose cotransporter-2 (SGLT2)
- Glucagon-like peptide (GLP-1) agonists
- Amylin Agonists
- By Distribution channel
- Retail pharmacies
- North America
- The U.S.
- Rest of North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- The Middle East and Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East and Africa
- Latin America
- Rest of Latin America
Increasing incidence of diabetes type 2 worldwide
Technological advancement in diabetes drugs
Rising diabetes diagnosis rates
The high cost of therapy
Lack of awareness in developing regions
Huge untapped market potential in emerging economies